NOTE: If you attended the live CE activity and received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-20-293-L01-P), you are ineligible to also receive CE credit for this home-study activity.
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
Pharmacists have rapidly expanded their roles as immunizers for the general public in multiple practice settings. However, much has changed over the past several years in the landscape of vaccine-preventable disease making it a challenge to keep up with the latest information. Many pharmacists can administer pneumococcal vaccines through statewide standing orders. This activity will provide a foundation on the impact of pneumonia, including risk factors and underlying conditions to consider when determining if a pneumococcal vaccine would be beneficial to individual patients. Faculty will focus on available vaccine products and their utility. Since the most common vaccine-related medication errors that occur in the community pharmacy setting involve the pneumococcal vaccines, special attention to product selection and administration will be provided.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
- Describe the clinical impact of pneumonia and risk factors for susceptibility.
- Identify patient populations at risk for the development of pneumonia and expert consensus recommendations for prophylactic vaccination.
- Compare and contrast pneumococcal vaccine products by dosing schedule.
- Examine best practices for pneumococcal vaccine administration.
Mary S. Hayney, PharmD, MPH
Professor of Pharmacy (CHS)
University of Wisconsin School of Pharmacy
Jeff Goad, Pharm.D., MPH, FAPhA, FISTM, FCPhA, FCSHP
Professor and Chair, Department of Pharmacy Practice
School of Pharmacy, Chapman University
Harry and Diane Rinker Health Science Campus
Release Date: 6-18-2020
Expiration Date: 8-06-2021
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-293-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Goad is a speaker for Merck, and a consultant for Emergent Biosolutions and Valneva. Dr. Hayney is a consultant for GSK Vaccines and Seqirus, and an investigator for Dynavax Technologies and Takeda. Potential conflict of interest was resolved with an outside peer review.
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.